Compare CALC & YMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALC | YMAT |
|---|---|---|
| Founded | 2011 | 1970 |
| Country | United States | Taiwan |
| Employees | N/A | 65 |
| Industry | Biotechnology: Pharmaceutical Preparations | Recreational Games/Products/Toys |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7M | 9.9M |
| IPO Year | 2020 | N/A |
| Metric | CALC | YMAT |
|---|---|---|
| Price | $0.84 | $0.78 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 290.5K | ★ 5.4M |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $2.86 | $10.92 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $0.24 |
| 52 Week High | $7.20 | $6.45 |
| Indicator | CALC | YMAT |
|---|---|---|
| Relative Strength Index (RSI) | 53.11 | 49.73 |
| Support Level | $0.52 | $0.32 |
| Resistance Level | $0.93 | $0.94 |
| Average True Range (ATR) | 0.11 | 0.30 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 23.11 | 16.93 |
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
J-Star Holding Co Ltd is engaged in the research, development, and manufacturing of carbon fiber for a wide variety-of-products including carbon bicycles, carbon rackets, automotive parts, outdoor sports gears, and healthcare products. The company has five segments: Bicycle frame, Racket, Crank, Service provision, and Others. The majority of its revenue is generated from the Bicycle frame segment. Geographically, the company operates in Taiwan, China, and other regions.